Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CT7/MAGE-A3/WT1 mRNA-electroporated LCs |
Synonyms | |
Therapy Description |
CT7/MAGE-A3/WT1 mRNA-electroporated LCs are autologous patient-derived Langerhans cells that are modifed to induce a cytotoxic T-cell response against cancer cells expressing MAGEC1 (CT7), MAGEA3, and WT1 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CT7/MAGE-A3/WT1 mRNA-electroporated LCs | CT7/MAGE-A3/WT1 mRNA-electroporated LCs are autologous patient-derived Langerhans cells that are modifed to induce a cytotoxic T-cell response against cancer cells expressing MAGEC1 (CT7), MAGEA3, and WT1 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01995708 | Phase I | CT7/MAGE-A3/WT1 mRNA-electroporated LCs | CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | Completed | USA | 0 |